Objective:HMP discussion with the effect of trimetazidine treatment of elderly patients with ischemic cardiomyopathy and heart failure associated with. Methods: A retrospective analysis of the First Affiliated Hospital of Chongqing Medical University, treated from March 2011 to December 2013 during the clinical data of 54 cases of elderly patients with ischemic cardiomyopathy and heart failure, according to the patient's admission into the tail number of the control group (alone trimetazidine) and Research group (HMP with trimetazidine combined with), 27 cases in each group. Clinical comparative study of two groups of patients, left ventricular ejection fraction, left ventricular end- systolic diameter, left ventricular end- diastolic diameter index, 6- minute walk test and evaluation of the probability of adverse reactions. The result:By six months after treatment, the 6- minute walk test evaluation study group of pa-tients with left ventricular end- diastolic diameter index, left ventricular end- systolic diameter, left ventricular ejection fraction and clin-ical total effective rate should be significantly better than patients in the control group, the difference statistically significant (P<0.05);incidence of adverse reactions in the control group and the study group was not statistically significant comparison (P>0.05). Conclu-sion:For elderly heart failure patients with ischemic cardiomyopathy, using HMP joint trimetazidine treatment with good clinical effica-cy, high security advantages, to enhance the quality of life of patients with a very important practical significance.
HMPTrimetazidineheart failureischemic heart disease in elderly
NETL
NSTL
万方数据
